Tandem Diabetes Care Announces Fourth Quarter and Full Year 2020 Financial Results and 2021 Financial Guidance
Tandem Diabetes Care reported strong financial results for Q4 and FY 2020, with worldwide pump shipments increasing 67% to 32,685 and sales rising 55% to $168.1 million compared to Q4 2019. For the full year, sales reached $498.8 million, a 38% increase, while the gross profit improved 34% to $260.5 million. The company anticipates 20-23% sales growth for 2021, estimating revenue between $600 million and $615 million, with a gross margin of approximately 55%.
- Q4 2020 worldwide pump shipments increased 67% to 32,685.
- Sales increased by 55% in Q4 2020 to $168.1 million.
- Full Year 2020 sales reached $498.8 million, a 38% increase.
- Expected sales growth of 20-23% for 2021.
- Net loss for 2020 was $34.4 million, worsening from a $24.8 million net loss in 2019.
- Adjusted EBITDA decreased to 12% of sales from 13% in 2019.
- Operating expenses rose to $268.5 million from $210.9 million in 2019.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter and year ended December 31, 2020 and financial guidance for the year ending December 31, 2021.
Fourth Quarter and Full Year 2020 Highlights
In comparing the fourth quarter of 2020 to the same period of 2019:
- Worldwide pump shipments increased 67 percent to 32,685 pumps
-
Sales increased 55 percent to
$168.1 million - Adjusted EBITDA(1) remained consistent at 21 percent of sales
- Operating margin improved to 11 percent
In comparing the year ended December 31, 2020 to the same period of 2019:
- Worldwide pump shipments increased 24 percent to 90,771 pumps
-
Sales increased 38 percent to
$498.8 million - Adjusted EBITDA(1) was 12 percent of sales compared to 13 percent in 2019
- Operating margin improved to negative 2 percent
“In 2020, we launched our best-in-class Control-IQ technology, surpassed the milestone of having more than 200,000 customers in our worldwide installed base, and made meaningful internal product development and operational progress, all under the constraints of the global pandemic,” said John Sheridan, president and chief executive officer. “In the year ahead, we remain focused on executing through operational excellence, delivering sustainable growth through our robust commercial offerings and product pipeline, and providing people worldwide a positively different experience in diabetes care.”
Fourth Quarter 2020 Financial Results
Worldwide pump shipments increased 67 percent to 32,685 pumps from 19,602 pumps. Worldwide sales increased 55 percent to
Gross profit for the fourth quarter of 2020 increased 50 percent to
For the fourth quarter of 2020, operating expenses totaled
Net income for the fourth quarter of 2020 was
Full Year 2020 Financial Results
Worldwide pump shipments increased 24 percent to 90,771 pumps from 73,431 pumps. Worldwide sales increased 38 percent to
Gross profit for the year ended 2020 increased 34 percent to
For the year ended 2020, operating expenses totaled
Net loss for the year ended 2020 was
Cash Balance and Liquidity
As of December 31, 2020, the Company had
2021 Financial Guidance
For the year ending December 31, 2021, the Company is providing its financial guidance as follows:
-
Sales are estimated to be in the range of
$600 million to$615 million , which represents an annual sales growth of 20 percent to 23 percent compared to 2020-
Includes international sales of approximately
$105 million to$110 million
-
Includes international sales of approximately
- Gross margin is estimated to be approximately 55 percent
- Adjusted EBITDA(1) is estimated to be 14 percent to 15 percent of sales
-
Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately
$80 million , which include:-
Approximately
$65 million in non-cash, stock-based compensation expense -
Approximately
$15 million of depreciation and amortization
-
Approximately
(1) |
See "Non-GAAP Financial Measures" below. EBITDA is a non-GAAP financial measure defined as net income (loss) excluding income taxes, interest and other non-operating items and depreciation and amortization. Adjusted EBITDA further adjusts for the change in fair value of common stock warrants and non-cash stock-based compensation expense. This definition of Adjusted EBITDA may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Adjusted EBITDA is a key measure used by the Company to evaluate operating performance, generate future operating plans and make strategic decisions for the allocation of capital. The Company presents Adjusted EBITDA to provide information that may assist investors in understanding its financial results. However, Adjusted EBITDA is not intended to be a substitute for net income (loss). |
Non-GAAP Financial Measures
Certain non-GAAP financial measures are presented in this press release, including adjusted EBITDA, to provide information that may assist investors in understanding the Company’s financial results and assessing its prospects for future performance. We believe these non-GAAP financial measures are important indicators of our operating performance because they exclude items that are unrelated to, and may not be indicative of, our core operating results. These non-GAAP financial measures, as we calculate them, may not necessarily be comparable to similarly titled measures of other companies and may not be appropriate measures for comparing the performance of other companies relative to the Company. These non-GAAP financial results are not intended to represent, and should not be considered to be more meaningful measures than, or alternatives to, measures of operating performance as determined in accordance with GAAP. To the extent we utilize such non-GAAP financial measures in the future, we expect to calculate them using a consistent method from period to period. A reconciliation of each of the GAAP financial measures to the most directly comparable non-GAAP financial measures has been provided under the heading “Reconciliation of GAAP versus Non-GAAP Financial Results” in the financial statement tables attached to this press release. Consistent with SEC regulations, we have not provided a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures in reliance on the “unreasonable efforts” exception set forth in the applicable regulations, because there is substantial uncertainty associated with predicting any future adjustments that we may make to our GAAP financial measures in calculating our non-GAAP financial measures.
Conference Call
The Company will hold a conference call and simultaneous webcast today at 4:30pm Eastern Time (1:30pm Pacific Time). The link to the webcast will be available by accessing the Events & Presentations tab in the Investor Center of the Tandem Diabetes Care website at http://investor.tandemdiabetes.com, and will be archived for 30 days. To listen to the conference call via phone, please dial 855-427-4396 (U.S./Canada) or 484-756-4261 (International) and use the participant code “7178576.”
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem’s flagship product, the t:slim X2 insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.
Tandem Diabetes Care is a registered trademark and t:slim X2 and Control-IQ are trademarks of Tandem Diabetes Care, Inc.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding, among other things, the Company’s projected financial results. The Company’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, the Company’s ability to achieve projected financial results will be impacted by market acceptance of the Company’s existing products and products under development by physicians and people with diabetes; the Company’s ability to establish and sustain operations to support international sales, including expansion into additional geographies; changes in reimbursement rates or insurance coverage for the Company’s products; the Company’s ability to meet increasing operational and infrastructure requirements from higher customer interest and a larger base of existing customers; the Company’s ability to complete the development and launch of new products when anticipated; the potential that newer products, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the Company’s products obsolete or less desirable; the depth and duration of the evolving COVID-19 pandemic, and the global response thereto; reliance on third-party relationships, such as outsourcing and supplier arrangements; global economic conditions; and other risks identified in the Company’s most recent Annual Report on Form 10-K and other documents that the Company files with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.
TANDEM DIABETES CARE, INC. |
|||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
|||||||
(in thousands) |
|||||||
|
|||||||
|
December 31, |
|
December 31, |
||||
|
2020 |
|
2019 |
||||
Assets |
|
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents and short-term investments |
$ |
484,936 |
|
|
$ |
176,458 |
|
Accounts receivable, net |
82,195 |
|
|
46,585 |
|
||
Inventories |
63,721 |
|
|
49,073 |
|
||
Other current assets |
6,383 |
|
|
4,025 |
|
||
Total current assets |
637,235 |
|
|
276,141 |
|
||
|
|
|
|
||||
Property and equipment, net |
50,022 |
|
|
32,923 |
|
||
Operating lease right-of-use assets |
19,773 |
|
|
15,561 |
|
||
Other long-term assets |
9,385 |
|
|
1,485 |
|
||
Total assets |
$ |
716,415 |
|
|
$ |
326,110 |
|
|
|
|
|
||||
Liabilities and Stockholders’ Equity |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable, accrued expenses and employee-related liabilities |
$ |
56,747 |
|
|
$ |
54,079 |
|
Deferred revenue |
6,082 |
|
|
3,869 |
|
||
Common stock warrants |
14,261 |
|
|
23,509 |
|
||
Operating lease liabilities |
9,421 |
|
|
6,320 |
|
||
Other current liabilities |
17,341 |
|
|
11,619 |
|
||
Total current liabilities |
103,852 |
|
|
99,396 |
|
||
|
|
|
|
||||
Convertible senior notes, net - long-term |
202,984 |
|
|
— |
|
||
Operating lease liabilities - long-term |
15,914 |
|
|
14,063 |
|||
Other long-term liabilities |
27,360 |
|
|
17,672 |
|
||
Total liabilities |
350,110 |
|
|
131,131 |
|
||
|
|
|
|
||||
Total stockholders’ equity |
366,305 |
|
|
194,979 |
|
||
Total liabilities and stockholders’ equity |
$ |
716,415 |
|
|
$ |
326,110 |
|
TANDEM DIABETES CARE, INC. |
||||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||||||
(in thousands, except per share data) |
||||||||||||||||||
|
||||||||||||||||||
|
(Unaudited) |
|
|
|
|
|||||||||||||
|
Three Months Ended
|
|
Year Ended December 31, |
|||||||||||||||
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|||||||||||
Sales |
$ |
168,065 |
|
|
|
$ |
108,398 |
|
|
$ |
498,830 |
|
|
|
$ |
362,305 |
|
|
Cost of sales |
77,509 |
|
|
|
48,126 |
|
|
238,310 |
|
|
|
168,093 |
|
|
||||
Gross profit |
90,556 |
|
|
|
60,272 |
|
|
260,520 |
|
|
|
194,212 |
|
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|||||||||||
Selling, general and administrative |
54,518 |
|
|
|
45,561 |
|
|
204,903 |
|
|
|
165,735 |
|
|
||||
Research and development |
17,376 |
|
|
|
12,567 |
|
|
63,574 |
|
|
|
45,199 |
|
|
||||
Total operating expenses |
71,894 |
|
|
|
58,128 |
|
|
268,477 |
|
|
|
210,934 |
|
|
||||
Operating income (loss) |
18,662 |
|
|
|
2,144 |
|
|
(7,957 |
) |
|
|
(16,722 |
) |
|
||||
Total other income (expense), net |
(1,624 |
) |
|
|
585 |
|
|
(28,325 |
) |
|
|
(7,882 |
) |
|
||||
Income (loss) before income taxes |
17,038 |
|
|
|
2,729 |
|
|
(36,282 |
) |
|
|
(24,604 |
) |
|
||||
Income tax expense (benefit) |
38 |
|
|
|
77 |
|
|
(1,900 |
) |
|
|
149 |
|
|
||||
Net income (loss) |
$ |
17,000 |
|
|
|
$ |
2,652 |
|
|
$ |
(34,382 |
) |
|
|
$ |
(24,753 |
) |
|
|
|
|
|
|
|
|
|
|||||||||||
Net income (loss) per share, basic |
$ |
0.27 |
|
|
|
$ |
0.04 |
|
|
$ |
(0.56 |
) |
|
|
$ |
(0.42 |
) |
|
Net income (loss) per share, diluted |
$ |
0.22 |
|
|
|
$ |
0.04 |
|
|
$ |
(0.56 |
) |
|
|
$ |
(0.42 |
) |
|
|
|
|
|
|
|
|
|
|||||||||||
Weighted average shares used to compute basic net income (loss) per share |
62,249 |
|
|
|
59,219 |
|
|
60,990 |
|
|
|
58,507 |
|
|
||||
Weighted average shares used to compute diluted net income (loss) per share |
65,677 |
|
|
|
62,883 |
|
|
60,990 |
|
|
|
58,507 |
|
|
||||
Reconciliation of GAAP versus Non-GAAP Financial Results
(in thousands) |
Three Months Ended December
|
|
Year Ended December 31, |
||||||||||||||||
|
2020 |
|
2019 |
|
2020 |
|
2019 |
||||||||||||
GAAP net income (loss) |
$ |
17,000 |
|
|
|
$ |
2,652 |
|
|
|
$ |
(34,382 |
) |
|
|
$ |
(24,753 |
) |
|
Income tax expense (benefit) |
38 |
|
|
|
77 |
|
|
|
(1,900 |
) |
|
|
149 |
|
|
||||
Interest income and other, net |
(332 |
) |
|
|
(812 |
) |
|
|
(1,567 |
) |
|
|
(3,193 |
) |
|
||||
Interest expense |
4,775 |
|
|
|
— |
|
|
|
12,805 |
|
|
|
— |
|
|
||||
Depreciation and amortization |
3,427 |
|
|
|
1,642 |
|
|
|
10,451 |
|
|
|
6,072 |
|
|
||||
EBITDA |
24,908 |
|
|
|
3,559 |
|
|
|
(14,593 |
) |
|
|
(21,725 |
) |
|
||||
Change in fair value of common stock warrants |
(2,819 |
) |
|
|
226 |
|
|
|
17,087 |
|
|
|
11,075 |
|
|
||||
Stock-based compensation expense |
13,308 |
|
|
|
18,684 |
|
|
|
58,431 |
|
|
|
58,071 |
|
|
||||
Adjusted EBITDA |
$ |
35,397 |
|
|
|
$ |
22,469 |
|
|
|
$ |
60,925 |
|
|
|
$ |
47,421 |
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005364/en/
FAQ
What were Tandem Diabetes Care's Q4 2020 financial results?
What is the sales forecast for Tandem Diabetes Care in 2021?
How did Tandem Diabetes Care perform in 2020 compared to 2019?
What is the gross margin expected for Tandem Diabetes Care in 2021?
What was Tandem Diabetes Care's adjusted EBITDA for 2020?
